Arrien Pharmaceutical’s is a new drug discovery company. Series A invested $ 2 million by founders. Seeking $10 million Series B by Q4 2014.
Arrien Pharmaceutical’s is a Pre-Clinical‐stage Biopharmaceutical company focused on the design and development of targeted novel small molecule First‐in Class Therapeutics using its proprietary FIELDS platform. Company currently focused on Rheumatoid Arthritis (RA), Multiples Sclerosis (MS), Psoriasis, Cancer (Ovarian, Breast, Prostate, DLBCL, Lung and GBM), Parkinson's, and Diabesity Diseases.